Anti-VEGF: The Next Generation

In this Feature

Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening Pigment Epithelium Detachment

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Conversion to Neovascular AMD in a Geographic Atrophy Patient With a 2-Year Treatment History

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

St<strike>ep</strike>upid Edits in a Neovascular AMD Patient

Stepupid Edits in a Neovascular AMD Patient

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-generation Therapies

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

About This Editorial Feature

Retina specialists are continuing their mission to explore new technologies treating wet AMD and DME, to seek out new means of reducing burden of care, and to boldly go where retina has not gone before!

Editorial Feature:

Anti-VEGF: The Next Generation

In this Feature